Pyridorin in type 2 diabetic nephropathy. - Wikidata - awgldk - TriplyDB

Pyridorin in type 2 diabetic nephropathy.

Pyridorin in type 2 diabetic nephropathy.

http://www.wikidata.org/entity/Q35720807

about

Vitamin B and its derivatives for diabetic kidney disease Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade Renal Biopsy in Type 2 Diabetic Patients Present and future in the treatment of diabetic kidney disease Site-specific AGE modifications in the extracellular matrix: a role for glyoxal in protein damage in diabetes Diabetic kidney disease: from physiology to therapeutics Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles.Diabetic nephropathy - complications and treatment.Emerging drugs for chronic kidney disease.Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney disease Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths.Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease Pyridoxamine protects proteins from damage by hypohalous acids in vitro and in vivo.Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease.Diabetic nephropathy: What does the future hold?Implications of treatment that target protective mechanisms against diabetic nephropathy 5'-O-Alkylpyridoxamines: Lipophilic Analogues of Pyridoxamine Are Potent Scavengers of 1,2-Dicarbonyls.Novel drugs and intervention strategies for the treatment of chronic kidney disease.Pretreatment with pyridoxamine mitigates isolevuglandin-associated retinal effects in mice exposed to bright light.Current therapeutic interventions in the glycation pathway: evidence from clinical studies.Glomerular disease in 2012: more mechanistic insights, but translational progress is slow.Emerging drugs for managing kidney disease in patients with diabetes.Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction.Have we reached the limits for the treatment of diabetic nephropathy?Therapeutic approaches to diabetic nephropathy--beyond the RAS.Natural product and natural product derived drugs in clinical trials.Novel effective drugs for diabetic kidney disease? or not?The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases.Species differences in regulation of renal proximal tubule transport by certain molecules New and old agents in the management of diabetic nephropathy.The next generation of therapeutics for chronic kidney disease Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?The Gomez' equations and renal hemodynamic function in kidney disease research.Novel avenues for treating diabetic nephropathy: new investigational drugs.Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention.Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury Involvement of advanced glycation end-products in 'hyperglycemic memory'.

P2860

Q24186641-EC3EE723-5C7A-4694-A02F-31B615BA7201 Q26799443-369E835F-6482-411E-992B-C34F67C5C3DB Q26799509-25B67284-5A0D-4F4F-9752-493B67157002 Q26864133-1E5F2005-2A62-4DA0-8BE9-FFC5A9C688A3 Q26865565-0E9203CB-4E66-4BBC-8E99-3F132694476B Q27021392-70564A6E-0E34-4C96-9BC5-03F4DD0AFE50 Q28086840-6B769926-9EE3-4FF6-9C58-E02DF235C36A Q28546969-68A9C992-422B-40FD-9DE4-24FDBF9CD100 Q30407920-BC4CC455-4F48-4E0B-AC60-0C3B878F2E1A Q34387952-45C1E06E-E65E-47FF-9821-F1C30ED24191 Q34420383-5D04C49F-91C1-4FC2-8C10-7213CF767E65 Q34787799-5E705596-2F7B-4174-9BE8-0C3688ADFCFC Q35214629-F16C5A9D-C611-4B99-9504-63D30A1FA29F Q35953867-BDA392FC-5A8A-460B-B12F-84A097763521 Q35995060-535A8234-3790-4FE0-A166-7DCD8CD3709E Q36386384-C409CA63-8D87-438C-BB3A-FA76175E1D87 Q36420791-65569ED7-3584-42A4-8BB4-5CC25C06C38E Q36441616-E9CF4F19-2478-4100-B44E-DE739004A579 Q36645971-D7E4F95B-7CE7-4D36-982B-D9FC2BF78951 Q37200477-91BB394A-7386-4906-83A6-FC24F35B08B6 Q37219043-8AD6D59A-944C-48AC-BDF6-388E8A71C27B Q37226073-2A4370C4-DD8F-4DD4-B376-E6315F030CD9 Q38070906-52493448-E4E1-474F-89F2-EC7F1195425D Q38072298-F145E06F-8233-44E1-ADA5-81E75BC7E3BB Q38075029-AFB4068F-98F0-45C5-8E55-DA8155B3B739 Q38118993-1FA586B3-368A-4ED6-910A-3C851CEE25AF Q38189884-0A7C32B4-D81E-43D5-ADC0-8E1D55394AEF Q38209811-D84B80C9-079D-4872-922B-8846EB51F761 Q38247457-AD2E981F-1433-47E1-B242-AAF7F159E6FF Q38265818-076B9F1B-1F2A-40E1-8039-16E51C11C302 Q38394355-556D4CDC-B362-4E56-A1A1-E2607F570993 Q38463854-0CA42FC8-53C1-4E3B-8FED-FF6419CBB7E1 Q38738871-10FD578C-0DB9-44A3-9FF7-28B0BBBE3307 Q38845590-1C31D70E-15C5-42AD-80CF-1600EF17C3CD Q38857652-3FAC77F7-51C5-4118-A943-FBDE3857DBB6 Q38949048-4791154D-FE76-4A53-802D-DD491152C2B4 Q39170387-FFCC84B6-7F02-4C7D-8292-12AD0E945A4F Q39285661-7B41445D-7652-4A20-8B7D-E23F54C5F2E0 Q39754544-243D2E58-3353-4C34-BBA1-EFAC5CAE5FF5 Q40716419-3A7CA1D1-95A7-4B90-AAEF-891207F628AF

P2860

Pyridorin in type 2 diabetic nephropathy.

http://www.wikidata.org/entity/Q35720807

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Pyridorin in type 2 diabetic nephropathy.

@ast

Pyridorin in type 2 diabetic nephropathy.

@en

type

label

Pyridorin in type 2 diabetic nephropathy.

@ast

Pyridorin in type 2 diabetic nephropathy.

@en

prefLabel

Pyridorin in type 2 diabetic nephropathy.

@ast

Pyridorin in type 2 diabetic nephropathy.

@en

P1433

Q35720807-FDB7F40C-827A-4099-825A-C0D74A3F7980

P1476

Q35720807-6865590E-521F-4B22-A5A1-3BA893E5AB22

P2093

Q35720807-0F74086D-F01A-4A66-83A2-E4FA4830115E

Q35720807-30B9653F-F731-4063-935E-52192CFFBBE2

Q35720807-36B49E14-D975-47D2-9548-58F5274A4CFA

Q35720807-406E3295-65D0-4D20-BC97-D7820B449FCA

Q35720807-46EE42BC-6EBF-4357-8EA6-7D48BBFF6699

Q35720807-47611AD2-28F8-4466-B457-789C9BCE3E55

Q35720807-A3181783-5054-402C-A5FD-F9B8C00E4E5F

Q35720807-C1508710-D778-4088-B307-C8C552DADAB3

Q35720807-C5900440-79EF-436A-AF7F-20E7B650C100

Q35720807-D6978C5F-7DBC-4E94-913F-1B87FACBFE21

P2860

Q35720807-18A641FE-AA83-4C08-9B42-1031054EF2F9

Q35720807-192EA7C8-6F05-4F12-AEB3-AB1A6B62E2A8

Q35720807-41AC50AE-ECDB-4F9C-9B45-5D63C5FB288B

Q35720807-841A3A84-A649-44FB-9BA4-FBD0947A92B8

Q35720807-8EF35975-DA6F-41F3-9608-380326D504BF

Q35720807-90551857-490C-4B52-92D3-684DE9880FD5

Q35720807-A38C5404-EDAD-4F6F-A52D-5AE87016E7CC

Q35720807-A6C0744D-2CEA-4B32-BD89-5D82DE5F1C55

Q35720807-B17AB03A-5DB9-4F82-B7E6-BCF04BA5E334

Q35720807-B44AC842-9BF3-48D1-BDA2-CD0530DA47D4

P304

Q35720807-9A50F57E-6497-4339-AD76-5DF44A3BB9EC

P31

Q35720807-D1269F63-C74E-4ABE-B50E-0403BB268F17

P356

Q35720807-67144666-1F05-4DD3-863A-98D1EC275C44

P433

Q35720807-58224B42-CD41-4C0E-92A7-AA7BEF05C70D

P478

Q35720807-D49AE70A-3F23-43DD-A8C7-C42F9FFC7020

P50

Q35720807-0C43B304-679E-4666-B99F-C0B1295BA469

P577

Q35720807-4A9D1CFB-11FA-4B34-8058-04E92BF4740A

P5875

Q35720807-DCF87028-8D85-490C-A1B4-05CB814D56C0

P698

Q35720807-54AD182A-5556-4AAA-BDF2-C20B7D8B5D1D

P932

Q35720807-927F8709-D11C-4D33-8E3F-1FAB3DC469EE

P356

P1433

Journal of the American Society of Nephrology

P1476

Pyridorin in type 2 diabetic nephropathy.

@en

P2093

Anne T Reutens

http://www.w3.org/2001/XMLSchema#string

David K Packham

http://www.w3.org/2001/XMLSchema#string

Edmund J Lewis

http://www.w3.org/2001/XMLSchema#string

Itamar Raz

http://www.w3.org/2001/XMLSchema#string

Julia B Lewis

http://www.w3.org/2001/XMLSchema#string

Lawrence G Hunsicker

http://www.w3.org/2001/XMLSchema#string

Marc A Pohl

http://www.w3.org/2001/XMLSchema#string

Richard D Rohde

http://www.w3.org/2001/XMLSchema#string

Robert C Atkins

http://www.w3.org/2001/XMLSchema#string

Samuel Blumenthal

http://www.w3.org/2001/XMLSchema#string

P2860

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.

Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.

Advanced protein glycosylation in diabetes and aging.

Structural-functional relationships in diabetic nephropathy.

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.

Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine.

A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation.

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes --- United States and Puerto Rico, 1996-2007.

P304

131-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2011030272

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Collaborative Study Group

P577

2011-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51752253

http://www.w3.org/2001/XMLSchema#string

P698

22034637

http://www.w3.org/2001/XMLSchema#string

P932

3269925

http://www.w3.org/2001/XMLSchema#string